Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
CXCR4
chemokines
molecular biomarker
renal cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Mar 2023
09 Mar 2023
Historique:
received:
01
12
2022
revised:
13
02
2023
accepted:
06
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
C-X-C Motif Chemokine Receptor 4 (CXCR4) is part of the human chemokine system and involved in progression and metastasis in renal cell carcinoma (RCC). However, the role of CXCR4 protein expression in RCC remains controversial. In particular, data regarding the subcellular distribution of CXCR4 in RCC and RCC metastasis as well as CXCR4 expression in renal tumors of variant histology are limited. The aim of the present study was the evaluation of the differential CXCR4 expression in RCC primary tumor and metastatic tissue as well as in variant renal histologies. In addition, the prognostic capacity of CXCR4 expression in organ-confined clear cell RCC (ccRCC) was evaluated. Three independent renal tumor cohorts (primary ccRCC cohort n
Identifiants
pubmed: 36982302
pii: ijms24065227
doi: 10.3390/ijms24065227
pmc: PMC10048828
pii:
doi:
Substances chimiques
Receptors, Chemokine
0
Biomarkers, Tumor
0
CXCR4 protein, human
0
Receptors, CXCR4
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Immunol. 2020 Aug 28;11:2109
pubmed: 32983169
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Oncol Lett. 2017 Dec;14(6):7513-7521
pubmed: 29344197
Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188790
pubmed: 36058380
Annu Rev Immunol. 2004;22:891-928
pubmed: 15032599
Int J Biochem Cell Biol. 2018 Feb;95:121-131
pubmed: 29288743
Cancer Sci. 2008 Mar;99(3):539-42
pubmed: 18201276
Br J Cancer. 2008 May 20;98(10):1682-9
pubmed: 18443596
J Cell Biochem. 2003 Jun 1;89(3):462-73
pubmed: 12761880
Clin Exp Nephrol. 2021 Oct;25(10):1057-1069
pubmed: 34109508
Br J Cancer. 2014 Apr 29;110(9):2261-8
pubmed: 24714746
Asian Pac J Cancer Prev. 2011;12(12):3313-8
pubmed: 22471472
PLoS One. 2013;8(2):e57194
pubmed: 23468933
Clin Cancer Res. 2011 Apr 15;17(8):2074-80
pubmed: 21349998
Dis Markers. 2015;2015:568980
pubmed: 26526157
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Ann Oncol. 2007 Jun;18(6):1021-9
pubmed: 17351259
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
Front Oncol. 2019 Aug 14;9:770
pubmed: 31475113
Biochim Biophys Acta. 2007 Apr;1768(4):952-63
pubmed: 17169327
Oncogene. 2019 Feb;38(6):881-895
pubmed: 30177838
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Clin Lung Cancer. 2017 May;18(3):e203-e210
pubmed: 28073681
Ann Surg Oncol. 2015 Mar;22(3):1026-31
pubmed: 25249257
Cell Death Dis. 2021 May 8;12(5):464
pubmed: 33966046
Clin Exp Metastasis. 2009;26(8):1049-54
pubmed: 19859817
Chin J Nat Med. 2018 Nov;16(11):801-810
pubmed: 30502762
N Engl J Med. 1998 Feb 12;338(7):436-45
pubmed: 9459648
J Oncol. 2008;2008:626340
pubmed: 19266088
World J Surg Oncol. 2012 Oct 07;10:212
pubmed: 23039915
Eur Urol. 2019 Jan;75(1):74-84
pubmed: 30243799
Anal Cell Pathol (Amst). 2015;2015:891020
pubmed: 26161302
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
Ann Diagn Pathol. 2021 Dec;55:151829
pubmed: 34563828
Target Oncol. 2016 Oct;11(5):643-653
pubmed: 27154357
J Cancer Res Clin Oncol. 2017 Jan;143(1):95-104
pubmed: 27638770
Histol Histopathol. 2013 Sep;28(9):1217-22
pubmed: 23609324
Cell Cycle. 2010 Nov 15;9(22):4492-4500
pubmed: 21127401
Mol Biol Rep. 2011 Feb;38(2):1039-45
pubmed: 20563655